Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., recently received a drug registration certificate from the Health Sciences Authority (HSA) of Singapore for its Rivaroxaban tablets. The approval allows the product to be marketed in Singapore. The registration covers three dosage strengths of the tablets (10mg, 15mg, and 20mg). This approval signifies that the product is now qualified for sale in Singapore, which is expected to have a positive impact on the company's efforts to expand its overseas market presence and provides valuable experience.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments